Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphom...( New York NY The Lymphoma Research Fo...),Health
New York, NY The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Nebraska.
Lymphoma, the most common type of blood cancer, is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to a 2008 report from the World Health Organization, there are six types of HL and over 61 types of NHL; many of which are rare diseases.
A member of LRF's Mantle Cell Lymphoma Consortium (MCLC), Dr. Fu's work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of NHL accounting for 6 percent of all new diagnoses of NHL or approximately 3,000 new cases per year in the United States. Mantle cell usually affects men over 60 and is frequently diagnosed as a Stage IV disease, often present in lymph nodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow.
MCL is characterized by over expression of the gene cyclin D1 due to a chromosomal translocation. A subset of MCL also expresses higher levels of a group of small RNA molecules, called miR-17~92. Dr. Fu and his co-workers have found that higher expression of miR-17~92 is directly correlated with poorer patient survival. These findings indicate that higher miR-17~92 expression induces abnormal activation of a pathway in tumor cells that leads to increased resistance to standard chemotherapy. Dr. Fu will conduct a pre-clinical study to determine whether suppression of miR-17~92 will improve the effect of chemotherapy. His study will thus provide a novel approach to treating MCL patients.
"Dr. Fu's elegant proposal explores a new avenue for understanding MCL and identifying potential therap
'/>"/>
| Contact: Marion F. Swan mswan@lymphoma.org 212-349-6435 Lymphoma Research Foundation Source:Eurekalert |
Related medicine news :
1. Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments
2. Armed Forces Retirement Home Selects Millenniums Pharmacy Services
3. Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
4. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
5. Industry Veteran Stephen Duvall Joins Millennium Management Team
6. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
7. Millennium Research Groups New Perception Pulse Product Offers Clients an Innovative New Customer Behavior and Loyalty Tracking Tool
8. Although the Health Care Market is Recession-Resistant, It Is Not Recession-Immune, According to Millennium Research Groups Medtech Economic Quarterly Publication
9. US Spinal Nonfusion Procedures Set to Increase Nearly Five Times From 2008 to 2013, According to Millennium Research Group
10. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
11. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |